Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Real-time Estimate Cboe BZX
Other stock markets
 03:08:47 2024-06-11 pm EDT 		5-day change 1st Jan Change
34.88 USD +1.81% Intraday chart for Kymera Therapeutics, Inc. +9.02% +36.76%
Jun. 01 Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting CI
May. 22 Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
CI
Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
CI
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting
CI
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
MT
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders
CI
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting
CI
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting
CI
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises
MT
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Kymera Therapeutics, Inc. Intends to Initiate A Phase 1 Clinical Trial in the Second Half of 2024 and Report the Phase 1 Results in 2025
CI
Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
CI
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474p
CI
Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474, a First-In-Class IRAK4 Degrader, in Nature Medicine
CI
Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
CI
Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
CI
Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
CI
Kymera Therapeutics Secures US FDA Fast Track Designation for Potential Lymphoma Treatment
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. News Kymera Therapeutics, Inc.
  5. Highlights